Metric Finance
LearnFAQ
LearnFAQ

Learn / ENTX

NASDAQ: ENTX

Entera Bio Ltd. (ENTX) stock, explained like you're 5

Entera Bio Ltd. trades on the Nasdaq under the ticker ENTX. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 463 million dollars.

Ticker
ENTX
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 463 million dollars

Is Entera Bio Ltd. a small, medium or large cap company?

No. Entera Bio Ltd. is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 463 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Entera Bio Ltd. makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves ENTX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • ENTX: Entera Bio Ltd Latest Stock Price, Analysis, News and Trading Ideas (Stocktwits)
  • ENTX Nov 2026 7.000 call (ENTX261120C00007000) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • A planned trial will test an osteoporosis pill in about 900 women (Stock Titan)
  • $ENTX stock is down 8% today. Here's what we see in our data. (Quiver Quantitative)
  • ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline (timothysykes.com)

Follow ENTX in your daily brief

Each trading day at 5 PM ET we post what happened to Entera Bio Ltd. and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow ENTX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Entera Bio Ltd. stock

What does Entera Bio Ltd. do?

Entera Bio Ltd. trades on the Nasdaq under the ticker ENTX. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 463 million dollars.

What is the ticker symbol for Entera Bio Ltd.?

Entera Bio Ltd. trades under the ticker ENTX on the Nasdaq.

What is Entera Bio Ltd.'s market cap?

Entera Bio Ltd. is a small cap stock with a market cap of about 463 million dollars.

How does Entera Bio Ltd. make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves ENTX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow ENTX stock every day?

Add ENTX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow ENTX daily

A free brief on Entera Bio Ltd. and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare ENTX: ENTX vs ARGX, ENTX vs RVMD, ENTX vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed